Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
JPMorgan Chase & Co. has filed a Schedule 13G reporting a passive ownership stake in LB Pharmaceuticals Inc. common stock. The firm reports beneficial ownership of 1,611,482 shares, representing 6.3% of the company’s outstanding common stock as of the event date.
JPMorgan has sole voting power over 1,471,295 shares and sole dispositive power over 1,611,482 shares, with no shared voting or dispositive power. The filing is certified as being made in the ordinary course of business and states that the securities are not held for the purpose of changing or influencing control of LB Pharmaceuticals.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake does JPMorgan Chase & Co. report in LBRX?
JPMorgan Chase & Co. reports beneficial ownership of 1,611,482 LB Pharmaceuticals common shares, representing 6.3% of the outstanding class.
Is JPMorgan’s position in LBRX reported as passive or active?
The position is reported on Schedule 13G with a certification that the shares were acquired and are held in the ordinary course of business, not to influence control.
How many LBRX shares can JPMorgan vote and dispose of?
JPMorgan has sole voting power over 1,471,295 shares and sole dispositive power over 1,611,482 shares, with no shared voting or dispositive power.
When did JPMorgan’s LBRX ownership level triggering this filing occur?
The date of the event requiring the filing is listed as 12/31/2025.
Which JPMorgan entities are associated with the LBRX holdings?
The filing identifies JPMorgan Chase Bank, National Association and J.P. Morgan Investment Management Inc. as relevant subsidiaries.
What type of reporting person is JPMorgan in this LBRX Schedule 13G?
JPMorgan Chase & Co. is classified as HC, a parent holding company or control person, under the Schedule 13G reporting categories.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
LB Pharmaceuticals Inc
(Name of Issuer)
Common Stock, $0.0001 par value
(Title of Class of Securities)
50180M108
(CUSIP Number)
12/31/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
50180M108
1
Names of Reporting Persons
JPMORGAN CHASE & CO.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
1,471,295.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
1,611,482.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,611,482.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.3 %
12
Type of Reporting Person (See Instructions)
HC
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
LB Pharmaceuticals Inc
(b)
Address of issuer's principal executive offices:
One Pennsylvania Plaza Suite 1025 New York NY 10119
Item 2.
(a)
Name of person filing:
JPMORGAN CHASE & CO.
(b)
Address or principal business office or, if none, residence:
270 Park Avenue,,New York, NY 10017
(c)
Citizenship:
DE
(d)
Title of class of securities:
Common Stock, $0.0001 par value
(e)
CUSIP No.:
50180M108
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
1611482
(b)
Percent of class:
6.3 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
1471295
(ii) Shared power to vote or to direct the vote:
0
(iii) Sole power to dispose or to direct the disposition of:
1611482
(iv) Shared power to dispose or to direct the disposition of:
0
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
JPMorgan Chase Bank, National Association;
J.P. Morgan Investment Management Inc.
Item 8.
Identification and Classification of Members of the Group.
If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
